

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

Article type : Full Length

Corresponding author mail id : [peter.sternes@qut.edu.au](mailto:peter.sternes@qut.edu.au)

HLA alleles associated with risk of ankylosing spondylitis and rheumatoid arthritis influence the gut microbiome

- Mark Asquith PhD<sup>1</sup>
- Peter R. Sternes PhD<sup>2</sup>
- Mary-Ellen Costello PhD<sup>2</sup>
- Lisa Karstens PhD<sup>3</sup>
- Sarah Diamond PhD<sup>1</sup>
- Tammy M. Martin PhD<sup>4</sup>
- Zhixiu Li PhD<sup>2</sup>
- Mhairi S. Marshall MSc<sup>2</sup>
- Timothy D. Spector PhD<sup>5</sup>
- Kim-Anh le Cao PhD<sup>6</sup>
- James T. Rosenbaum MD<sup>7\*</sup>
- Matthew A. Brown MBBS, MD<sup>2\*</sup>

\*These two authors contributed equally to this manuscript.

<sup>1</sup>Division of Arthritis and Rheumatic Diseases, Department of Ophthalmology, Oregon Health and Science University, Portland, USA.

<sup>2</sup>Translational Genomics Group, Institute of Health and Biomedical Innovation at Translational Research Institute, Queensland University of Technology, Brisbane, Australia.

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1002/ART.40917](https://doi.org/10.1002/ART.40917)

This article is protected by copyright. All rights reserved

33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69

<sup>3</sup>Division of Bioinformatics and Computational Biology, Oregon Health and Science University, Portland, OR, USA; Division of Urogynecology, Oregon Health and Science University, Portland, OR, USA.

<sup>4</sup>Casey Eye Institute, Oregon Health & Science University, Portland, OR, USA.

<sup>5</sup>Department of Twin Research and Genetic Epidemiology, King's College London, London, UK.

<sup>6</sup>Melbourne Integrative Genomics and School of Mathematics and Statistics, University of Melbourne, Melbourne, Victoria, Australia.

<sup>7</sup>Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health & Sciences University and Department Chair, Legacy Devers Eye Institute, both in Portland, OR, USA.

Corresponding Author:

Professor Matthew A. Brown,  
Institute of Health and Biomedical Innovation,  
Queensland University of Technology,  
Translational Research Institute,  
Princess Alexandra Hospital,  
Woolloongabba, Brisbane,  
Australia.  
Telephone: +61 7 3443 7366  
Fax : +61 7 3443 7102  
matt.brown@qut.edu.au

## ABSTRACT

Objectives. HLA alleles affect susceptibility to more than 100 diseases, but the mechanisms to account for these genotype-disease associations are largely unknown. HLA-alleles strongly influence predisposition to ankylosing spondylitis (AS) and rheumatoid arthritis (RA). Both AS and RA patients have discrete intestinal and faecal microbiome signatures. Whether these changes are cause or consequence of the diseases themselves is unclear. To distinguish these possibilities, we examine the effect of *HLA-B27* and *HLA-DRB1* RA-risk alleles on the composition of the intestinal microbiome in healthy individuals.

70 Methods. 568 samples from 6 intestinal sites were collected from 107 otherwise healthy unrelated  
71 subjects and stool samples from 696 twin pairs from the TwinsUK cohort. Microbiome profiling was  
72 performed using sequencing of the 16S rRNA bacterial marker gene. All patients were genotyped  
73 using the Illumina CoreExome SNP microarray, and HLA genotypes were imputed from these data.

74  
75 Results. Association was observed between *HLA-B27* genotype, and RA-risk *HLA-DRB1* alleles, and  
76 overall microbial composition ( $P=0.0002$  and  $P=0.00001$  respectively). These associations were  
77 replicated in the TwinsUK cohort stool samples ( $P=0.023$  and  $P=0.033$  respectively).

78  
79 Conclusions. This study shows that the changes in intestinal microbiome composition seen in AS and  
80 RA are at least partially due to effects of *HLA-B27* and *-DRB1* on the gut microbiome. These findings  
81 support the hypothesis that HLA alleles operate to cause or increase the risk of these diseases  
82 through interaction with the intestinal microbiome, and suggest that therapies targeting the  
83 microbiome may be effective in their prevention and/or treatment.

84  
85 Keywords

86 Ankylosing spondylitis, rheumatoid arthritis, microbiome.

## 87 INTRODUCTION

88 HLA molecules affect susceptibility to many diseases, but in the majority of cases the mechanism by  
89 which HLA molecules predispose to disease remains a mystery. The risks of developing both  
90 ankylosing spondylitis (AS) and rheumatoid arthritis are primarily driven by genetic effects, with  
91 heritability  $>90\%$  (1, 2) for AS, and 53-68% for RA (3, 4). In both diseases HLA alleles are the major  
92 susceptibility factors, with AS being strongly associated with *HLA-B27*, and RA with *HLA-DRB1*  
93 'shared-epitope' (SE) alleles.

94  
95 Particularly in AS, there is strong evidence of a role for gut disease in disease pathogenesis. Up to an  
96 estimated 70% of AS patients have either clinical or subclinical gut disease, suggesting that intestinal  
97 inflammation may play a role in disease pathogenesis (5, 6). Increased gut permeability has been  
98 demonstrated in both AS patients and their first-degree relatives compared with unrelated healthy  
99 controls (7-11). Crohn's disease (CD) is closely related to AS with a similar prevalence and high  
100 heritability. The two commonly co-occur with an estimated  $\sim 5\%$  of AS patients developing CD, and 4-  
101 10% of CD patients developing AS (12, 13). Strong co-familiality (14), and the extensive sharing of  
102 genetic factors between AS and inflammatory bowel disease (IBD) (15, 16) suggests that they have a

103 shared aetiopathogenesis. This is consistent with the hypothesis that gut derived immune cells or  
104 microbial products may contribute to spondyloarthritic inflammation (17-19).

105

106 Using 16S rRNA community profiling we have previously demonstrated that AS cases have a discrete  
107 intestinal microbial signature in the terminal ileum (TI) compared with healthy controls (HC)  
108 ( $P < 0.001$ ) (20), a finding that has subsequently been confirmed by other studies (21, 22). We have  
109 also demonstrated that dysbiosis is an early feature of disease in *HLA-B27* transgenic rats, preceding  
110 the onset of clinical disease in the gut or joints (23). Similarly, RA cases have also been shown to  
111 have gut dysbiosis (24, 25), and animal models of RA such as collagen-induced arthritis have been  
112 shown to be influenced by the gut microbiome (26, 27). In these studies it is difficult to distinguish  
113 between effects of the immunological processes going on in the intestinal wall in cases, and the  
114 effects of treatments on the intestinal microbiome, from potential effects of the gut microbiome on  
115 the disease.

116

117 The role of the host genetics in shaping intestinal microbial community composition in humans is  
118 unclear. In animal models, host gene deletions have been shown to result in shifts in microbiota  
119 composition (28). In addition, a recent quantitative trait locus mapping study in an inter-cross  
120 murine model, linked specific genetic polymorphisms with microbial abundances (29). Large scale  
121 studies in twins ( $n=1126$  twin pairs) have demonstrated that of 945 widely shared taxa, 8.8% showed  
122 significant heritability, with some taxa having heritability of  $>40\%$  (e.g. family *Christensenellaceae*,  
123 heritability 42%) (30).

124

125 Further studies are needed into whether the changes in intestinal microbial composition are due to  
126 host genetics, and how this affects the overall function of the gut microbiome in cases, including  
127 how the microbiome then goes on to shape the immune response and influence inflammation. In  
128 AS, given the strong association of *HLA-B27*, the hypothesis has been raised that *HLA-B27* induces AS  
129 by effects on the gut microbiome, in turn driving spondyloarthritis and inducing immunological  
130 processes such as IL-23 production (31, 32). Further experiments comparing the intestinal  
131 microbiome of *HLA-B27* negative and positive patients would shed light of the influence of *HLA-B27*  
132 on overall intestinal microbiome composition, particularly given the work in *HLA-B27* transgenic rats  
133 showing that *HLA-B27* was associated with altered ileal, caecal, colonic and fecal microbiota (23, 33,  
134 34). Similar theories have been proposed with regard to interaction between the gut microbiome  
135 and the immunological processes that drive RA (reviewed in (35)).

136

137 In this study we investigated if AS and RA-associated HLA alleles influence the gut microbiome in  
138 healthy individuals, to support the hypothesis that they influence the risk of developing AS and RA  
139 through effects on the gut microbiome.

## 140 METHODS

### 141 Human subjects

142 A total of 107 subjects, aged 40-75, predominately Caucasian (~90%), typically following an  
143 omnivorous diet (~95%) and were undergoing routine colorectal cancer screening at Oregon Health  
144 & Science University's Center for Health and Healing were included in this study. Individuals were  
145 excluded if they had a personal history of inflammatory bowel disease or colon cancer, prior bowel  
146 or intestinal surgery or were pregnant. All subjects underwent a standard polyethylene glycol bowel  
147 prep the day prior to their colonoscopy procedure. During the procedure, biopsies were collected for  
148 research purposes from the terminal ileum or other tissue sites as indicated. Subjects were  
149 instructed to collect a stool sample on a sterile swab at home, just prior to starting their bowel prep  
150 procedure. Stool samples were brought to the colonoscopy appointment at room temperature. All  
151 samples (biopsies and fecal swabs) were placed at 4°C in the clinic and transported to the lab within  
152 2 hours of the colonoscopy procedure, where they were snap frozen and stored at -80°C prior to  
153 processing. Patient samples were obtained over a 24-month period.

154  
155 Ethical approval for this study was obtained from the Oregon Health & Science University  
156 Institutional Review Board. Written informed consent was obtained from all subjects. This study was  
157 performed subject to all applicable U.S. Federal and State regulations.

### 158 159 TwinsUK

160 All work involving human subjects was approved by the Cornell University IRB (Protocol ID  
161 1108002388). Matched genotyped and stool samples were collected from 1392 twins. Genotyping,  
162 16S rRNA amplicon sequencing, filtering and analysis were performed as described in Goodrich *et*  
163 *al.*, 2014 (36).

### 164 165 166 16S rRNA amplicon sequencing and analysis

167 568 stool and biopsy samples across 107 individuals were extracted and amplified for the bacterial  
168 marker gene 16S rRNA as previously described (20). Samples were demultiplexed and filtered for  
169 quality using the online platform BaseSpace (<http://basespace.illumina.com>). Paired end reads were  
170 joined, quality filtered and analysed using Quantitative Insights Into Microbial Ecology (QIIME) v1.9.1

171 (37). Operational taxonomy units (OTU) were picked against a closed reference and taxonomy was  
172 assigned using the Greengenes database (gg\_13\_8) (38), clustered at 97% similarity by UCLUST (39)  
173 and low abundance OTUs were removed (<0.01%).

174

175 Data visualization and statistical analysis

176 Multidimensional data visualisation was conducted using a sparse partial least squares discriminant  
177 analysis (sPLSDA) on centered log ratio transformed data, as implemented in R as part of the  
178 MixOmics package v6.3.1 (40). Association of the microbial composition with metadata of interest  
179 was conducted using a PERMANOVA test as part of vegan v2.4-5 (41) on arcsine square root  
180 transformed data at species level, taking into account individual identity where multiple sites per  
181 individual were co-analysed, as well as the sources of covariation such as BMI and gender. Alpha  
182 diversity was calculated at species level using the rarefy function as implemented in vegan v2.4-5  
183 and differences were evaluated using a Wilcoxon rank-sum test. The metagenome functional  
184 content was predicted using PICRUSt v1.1.3 (42) and the resulting predictions were mapped to KEGG  
185 pathways using HUMAnN2 v0.11.1 (43) Differential abundance of bacterial taxa and KEGG pathways  
186 were tested for significance using MaAsLin v0.0.5 (44).

187

188

189

190

191

192 Genotyping

193 DNA was extracted from mucosal biopsies and stool samples, and genotyped using Illumina  
194 CoreExome SNP microarrays according to standard protocols. Bead intensity data were processed  
195 and normalized for each sample, and genotypes called using Genome Studio (Illumina). We imputed  
196 *HLA-B* genotypes using SNP2HLA (45), as previously reported (46). The distribution of *HLA-B27* and  
197 *HLA-DRB1* RA-risk, -protective and -neutral subtypes is available in Supplementary Table 1.

198

199 RESULTS

200 16S rRNA profiling and SNP array genotyping was successfully completed for 107 individuals (61  
201 female, 46 male) involving a total of 564 biopsy samples (see Table 1).

202

203 We studied the effect of BMI, gender and sampling site on the gut microbiome to identify relevant  
204 covariates for analysis of AS-associated genes and their association with the gut microbiome.

205 Considering sample site, striking differences were observed, particularly between the stool samples  
206 and mucosal samples (Figure 1A,  $P < 0.0001$ ). Excluding stool samples, marked difference was still  
207 observed between sites ( $P < 0.0001$ ), but it can be observed that this is mainly driven by differences  
208 of the ileal samples from the colonic mucosal samples (left and right colon, cecum, rectum), which  
209 largely clustered together (Figure 1B).

210  
211 Stool samples are much more convenient to obtain than ileal or colonic mucosal samples, which  
212 require an endoscopic procedure for collection. Given the prior evidence of primarily ileal  
213 inflammation in AS (5), we were interested in the relationship between the ileal and stool  
214 microbiome. In this comparison marked differences were observed between sites, though with some  
215 overlap seen on the sPLSDA plot (Supplementary Figure 2,  $P < 0.0001$ ).

216  
217

Site	Total	Female	Male	HLA-B27 Negative	HLA-B27 Positive	HLA-DRB1 Risk Genotype	HLA-DRB1 Protective Genotype	HLA-DRB1 Neutral Genotype
Cecum	103	59	44	93	10	34	8	47
Ileum	90	51	39	80	10	36	8	45
Left Colon	100	57	43	90	10	33	7	47
Rectum	91	53	38	81	10	33	7	41
Right Colon	97	57	40	87	10	33	8	45
Stool	83	46	37	73	10	29	8	36

218  
219

220 Table 1: Number of samples and *HLA-B27* and *HLA-DRB1* shared epitope allele status by site. Note  
221 that different subjects had different numbers of samples obtained, and at no individual site did all  
222 subjects have samples obtained.

223  
224 Several studies have noted an increase (47), decrease (20, 21) or no change (48) in alpha diversity  
225 metrics for AS cases, and an increase (22) or decrease (49) in alpha diversity for RA cases. In the  
226 current study, calculation of rarefied species richness revealed that carriage of *HLA-B27* and *HLA-*  
227 *DRB1* alleles was not associated with differences in alpha diversity, except for stool samples for

228 which carriage of *HLA-DRB1* RA-risk alleles was associated an increased alpha diversity across both  
229 cohorts (Figure 2).

230 Considering beta diversity via sPLSDA and PERMANOVA, significant association of BMI category was  
231 seen with microbiome composition ( $P=0.0022$ )(Supplementary Figure 3A). This appears to be driven  
232 particularly by the difference of underweight individuals ( $BMI<18.5$ ) compared with other BMI  
233 categories. Removing underweight samples from the analysis, a non-significant trend of association  
234 of BMI category with microbiome composition is seen ( $P=0.078$ )(Supplementary Figure 3B),  
235 consistent with previous reports (50-52).

236 Given the marked gender biases in RA and AS, and evidence in mice that gender related hormonal  
237 differences are associated with differences in the intestinal microbiome (53, 54), we sought to  
238 evaluate the influence of gender on the microbiome in this cohort. Whilst substantial overlap  
239 between males and females was evident (Supplementary Figure 4), significant difference between  
240 genders in microbiome composition was observed (considering all sites,  $P=0.0004$ ). Considering  
241 indicator species, a significant reduction in carriage of *Prevotella* genus in males was observed  
242 ( $P=0.005$ ).

243

244 Controlling for BMI and gender, significant differentiation of the microbiome was identified in  
245 individuals carrying *HLA-B27* or RA-risk *HLA-DRB1* alleles (PERMANOVA  $P=0.002$  and  $P=0.0001$ ,  
246 respectively)(Figures 3A and 3B). Despite significant differentiation in terms of beta diversity, there  
247 was typically no difference in alpha diversity (Figure 2), indicating that the underlying host genetics  
248 may affect the overall composition of the microbiome, but not the overall species diversity. In the  
249 TwinsUK cohort, consisting of stool samples, and studying one twin drawn randomly from each twin  
250 pair, association with *HLA-B27* and RA-risk *HLA-DRB1* alleles was also observed ( $P=0.023$  and  
251  $P=0.033$  respectively, Figure 3C). Study of the alternate twin from each pair revealed consistent  
252 findings. Whether the observed differences in taxonomic and functional composition are consistent  
253 between the two cohorts remains an open-ended question as they are confounded by differences in  
254 the experimental approach and the surveyed population.

255 We tested whether HLA-B alleles associated with AS were also associated with gut microbial profiles.  
256 The association of HLA-B alleles with AS is complex, with risk associations observed with *HLA-B27*, -  
257 *B13*, -*B40*, -*B47* and -*B51*, and protective associations with *HLA-B7* and -*B57* (55). Of these, only  
258 *HLA-B27* showed statistically significant association with microbiome profile across both cohorts.  
259 Differences in the microbiome composition were more pronounced when comparing risk-associated  
260 alleles to protective alleles. For example, when focusing on a subset of data (ileal samples), marginal  
261 differentiation for -*B27* ( $P=0.16$ ) and no differentiation for -*B7* ( $P=0.61$ ) was observed, potentially



262 highlighting sample size constraints. However, direct comparison of *-B27* to *-B7* revealed significant  
263 differentiation ( $P=0.008$ ).

264

265 *HLA-B27*-positive subjects exhibited reduced carriage ( $P<0.05$ ) of *Bacterioides ovatus* across multiple  
266 sites (ileum, cecum, left colon, right colon and stool), as well as *Blautia obeum* (left colon and right  
267 colon) and *Dorea formicigenerans* (rectum and stool). Increased carriage of a *Roseburia* species was  
268 observed across multiple sites (left colon, right colon, rectum and stool) and family *Neisseriaceae*  
269 (cecum and ileum). For subjects with RA-risk *HLA-DRB1* alleles, numerous taxonomic groups were  
270 enriched across multiple sites, notably a *Lachnospiraceae* species (ileum, cecum, left colon, right  
271 colon and rectum), a *Clostridiaceae* species (left colon, right colon, rectum and stool)  
272 *Bifidobacterium longum* (cecum, right colon and rectum), amongst many others. Enrichment of  
273 *Ruminococcus gnavus* was also observed in the ileum of subjects carrying risk alleles. A full list of  
274 differently abundant taxa according to *HLA-B27* and *HLA-DRB1* status are available in Supplementary  
275 Tables 2 and 3, respectively. Interestingly, when accounting for false discovery rate, no single taxa  
276 was significantly associated with the investigated genotypes, indicating that community-level  
277 differences detectable via PERMANOVA may be driven by subtle changes in a high number of taxa,  
278 as opposed to marked changes in a select few.

279

280 Considering the inferred metabolic profiles for *HLA-B27* positive and negative subjects, we observed  
281 significant differences ( $P<0.05$ ) across multiple sites for numerous KEGG pathways (Supplementary  
282 Table 4). Examples include flagellar assembly (ileum, cecum, left colon, right colon and rectum),  
283 alanine metabolism (cecum, ileum, left colon, and right colon), lysine biosynthesis (left and right  
284 colon) and degradation (ileum, rectum and stool) and secondary bile acid biosynthesis (ileum and  
285 stool). For the RA-risk alleles (*HLA-DRB1*), numerous differences in KEGG pathways were observed  
286 (Supplementary Table 5). Examples include thiamine metabolism, the citric acid cycle,  
287 lipopolysaccharide biosynthesis, glycerolipid metabolism biosynthesis of ansamycins, RNA transport  
288 and bacterial chemotaxis, all of which were differentially abundant across every tissue site biopsied.

289 DISCUSSION

290 In this study we have demonstrated for the first time that in the absence of disease or treatment,  
291 *HLA-B27* and *HLA-DRB1* have significant effects on the gut microbiome in humans. This is consistent  
292 with *HLA-DRB1*-associated observations in mice (56) and the effect of *HLA-DRB1* alleles upon  
293 *Prevotella copri* abundance in humans (24). This extends previous demonstrations that AS and RA  
294 are characterized by intestinal dysbiosis by confirming that this is at least in part due to the effects of  
295 the major genetic risk factors for AS and RA, *HLA-B27* and *HLA-DRB1* risk alleles, respectively.

296

297 We demonstrate a clear distinction in microbiome profile between luminal stool samples and  
298 mucosal samples, as well as between mucosal samples from different intestinal sites. Of particular  
299 note, marked difference was observed between ileal and stool samples. These findings contrast a  
300 previous smaller study, which may not have observed a difference between ileal and colonic biopsies  
301 due to sample size considerations (48). Many studies of the influence of gut microbiome focus on  
302 stool samples, as they are easier to obtain than mucosal samples. The existence of gut inflammation,  
303 particularly involving the ileum, in AS cases has been well documented. Therefore, our findings  
304 suggest that studies of the microbiome in AS and RA, particularly where the aim is to identify the key  
305 species or genetic elements driving or protecting from the disease, should use samples that reflect  
306 the site of inflammation (i.e. at least in AS, ideally the ileal microbiome). As the microbiome profile  
307 of stool samples do not closely correlate with the ileal microbiome, they would not appear to be an  
308 optimal sample to study, although studying IgA coated bacteria isolated from stool samples may  
309 prove more informative (57, 58).

310

311 Following our initial study, three further studies have now reported on the difference in gut  
312 microbial composition in AS cases and controls. Tito et al (48) in a study of 27 spondyloarthritis  
313 patients (i.e. not necessarily AS) and 15 healthy controls using 16S rRNA profiling report association  
314 of carriage of *Dialister* in ileal or colonic mucosal biopsies with disease activity assessed by the self-  
315 reported questionnaire the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and  
316 Ankylosing Spondylitis Disease Activity Score (ASDAS). We did not observe *Dialister* in our study and  
317 therefore cannot comment on whether it is associated with *HLA-B27* carriage. Tito et al did not  
318 observe association of the gut microbiome with *HLA-B27* carriage, but the sample size, particularly in  
319 healthy controls, was too small to exclude other than a large effect. Wen et al used shotgun  
320 sequencing of stool samples from in 97 Chinese AS cases and 114 healthy controls, and reported  
321 significant dysbiosis in the AS cases (21). Breban et al (22) used 16S rRNA profiling of the stool  
322 microbiome to study 87 +-patients with axial spondyloarthritis (42 with AS), 69 healthy controls and  
323 28 rheumatoid arthritis patients. They also report evidence of intestinal dysbiosis in the  
324 spondyloarthritis patients, and report correlation of *Ruminococcus gnavus* carriage with BASDAI.  
325 Whilst we did not observe an association with the carriage of *HLA-B27*, *Ruminococcus gnavus* was  
326 noted to be enriched in the ileum of individuals carrying the *HLA-DRB1* RA-risk alleles  
327 (Supplementary Table 3). In a comparison of *HLA-B27* positive and negative siblings (n=22 and 21  
328 respectively), no difference in microbial composition was noted overall, but *HLA-B27* positive siblings  
329 had increased carriage of the *Microcaccaceae* family (including the species *Rothia mucilaginosa*

330 within it), several *Blautia* and *Ruminococcus* species, and of *Egerthella lenta*. They also observed a  
331 reduced carriage of *Bifidobacterium* and *Odoribacter* species. Of these we also see reduction in  
332 *Blautia obeum*. Although we did not find dysbiotic changes that were shared with these specific taxa,  
333 we note the enrichment of genera within the Lachnospiraceae-Ruminococcaceae grouping in HLA-B27  
334 carriers was a shared feature of our studies; *Roseburia* and *Ruminococcus* by Breban et al (22) and  
335 *Roseburia*, *Blautia*, *Dorea* and *Oscillospira* in our current study. These bacteria are known to be  
336 enriched within the intestinal mucosa (59), and are plausibly more immunogenic as a result (60). The  
337 differences observed between these studies may relate to analytical differences such as handling of  
338 covariates, disease definition, sample site studied, ethnicity and diet, and the different methods  
339 employed to profile the microbiome. Our study also confirms the significant effect of gender and  
340 BMI category on gut microbial profiles, suggesting that future studies should control for these  
341 covariates. Consistent with a recent study which examined the effect of the host's genetics upon the  
342 microbiome of 1,046 healthy individuals (61), numerous correlations between specific bacterial taxa  
343 and the host's genotype do not remain significant following correction for false discovery rate, thus  
344 indicating that HLA molecules may have a more generalized effect upon microbiome composition as  
345 opposed to a marked effect upon specific taxa. Despite this, we note that many of the  $P < 0.05$   
346 associations occurred across multiple tissue sites. Whilst the chance of a false positive at a single site  
347 might be relatively high, the chances of finding the same association across multiple sites decreases  
348 exponentially, indicating that the results are less likely to be spurious. Another possibility is that  
349 differences in microbial gene content, not necessarily specific taxa, may be more significant. In the  
350 current study, the microbiome's predicted gene content was extrapolated from the underlying  
351 taxonomy, therefore utilization of whole genome sequencing metagenomics (a.k.a. shotgun  
352 metagenomics) to directly profile genetic composition may prove fruitful. This will be the focus of  
353 subsequent studies.

354  
355 HLA molecules affect susceptibility to many diseases, most of which are immunologically mediated.  
356 In almost all instances, the mechanism that accounts for that predisposition is not known. The  
357 microbiome has now been implicated in a long list of diseases, many of which are immunologically  
358 mediated. Our studies suggest that HLA molecules could be important factors that contribute to the  
359 heterogeneity of the microbiome and operate at least partially through this mechanism in the  
360 pathogenesis of many different diseases, not just AS and RA. Consistent with this hypothesis, HLA-  
361 microbiome associations have been described in reactive arthritis (62), IBD (63), celiac disease (64)  
362 and in healthy individuals (24, 65).

363

364 The hypothesized metabolic changes imbued by dysbiosis in our current work are of interest in light  
365 of a recent study by our group in the *HLA-B27* transgenic rat model of spondyloarthritis (66). We  
366 observe a number of *HLA-B27* dependent metabolic changes in this model that include enrichment  
367 of bile acid metabolism, lysine metabolism, fatty acid metabolism and tryptophan metabolism. All of  
368 these pathways were predicted to be enriched in *HLA-B27* positive individuals in our current study  
369 (Supplementary Table 4). Importantly, *HLA-B27*-dependent dysbiosis can be observed prior to the  
370 onset of disease in this model. Thus, our human and rat studies support the hypothesis that *HLA-B27*  
371 dependent dysbiosis is a preceding event in AS pathogenesis and may not merely be secondary to  
372 disease.

373  
374 In conclusion, this study demonstrates that *HLA-B27* and RA-associated *HLA-DRB1* allele carriage in  
375 humans influences the gut microbiome. In association with the replicated demonstration of  
376 intestinal changes in microbiome in AS, this is consistent with disease models in which HLA  
377 molecules interact with the gut microbiome to cause disease. Different models as to how this may  
378 occur include effects of *HLA-B27* to favour a more inflammatory gut microbiome, increased  
379 invasiveness of the gut mucosa in *HLA-B27* carriers, and/or aberrant immunological responses to  
380 bacteria in *HLA-B27* carriers. Similar hypotheses may explain the role of *HLA-DRB1* in driving the  
381 immunopathogenesis of RA. Whichever of these models is correct, the data presented here support  
382 further research in this field, including into whether manipulation of the gut microbiome may be  
383 therapeutic in AS or RA, or even potentially capable of preventing disease in at risk subjects.

384  
385  
386  
387 Figure 1: sPLSDA comparing the microbiome composition at various sample sites, showing A. marked  
388 difference of stool/luminal site compared with all other sites, which are mucosal, and B. in the  
389 absence of stool samples, the ileal site remains distinct from colonic sites. A PCA plot of these results  
390 is available in Supplementary Figure 1.

391  
392 Figure 2: Alpha diversity across each sampling site, and in the TwinsUK cohort A. Alpha diversity  
393 according *HLA-B27* status. B. Alpha diversity according to *HLA-DRB1* status, revealing increased alpha  
394 diversity in stool samples of both cohorts.

395  
396 Figure 3: A. sPLSDA comparing the microbiome composition of *HLA-B27* positive and negative  
397 individuals across each sampling site. Considering all sampling sites and accounting for repeated

398 sampling, significant differentiation of the microbiome was observed (PERMANOVA  $P=0.002$ ). B.  
399 sPLSDA comparing individuals carrying the *HLA-DRB1* RA-risk and -neutral genotypes across each  
400 sampling site. Considering all sites and accounting for repeated sampling, significant differentiation  
401 of the microbiome was observed (PERMANOVA  $P=0.0001$ ). C. sPLSDA plot comparing *HLA-B27*  
402 positive and negative twins (one twin randomly selected from each twin pair, PERMANOVA  
403  $P=0.023$ ), and *HLA-DRB1* risk and neutral genotypes (one twin randomly selected from each twin  
404 pair, PERMANOVA  $P=0.033$ ). PCA plots of these results are available in Supplementary Figure 5.

405

#### 406 ACKNOWLEDGEMENTS

407 MAB is funded by a National Health and Medical Research Council (Australia) Senior Principal  
408 Research Fellowship. This work was funded by a National Health and Medical Research Council  
409 (Australia) project grant (reference APP1065509). MA and JTR receive funding from the Spondylitis  
410 Association of America and the Rheumatology Research Foundation and from NIH Grant RO1  
411 EY029266. TDS is a National Institute for Health Research (NIHR) senior investigator. TwinsUK is  
412 funded by the Wellcome Trust, Medical Research Council, CDRF, Arthritis Research UK, European  
413 Union, the NIHR – funded Clinical Research Facility and Biomedical Research Centre based at Guy’s,  
414 and St. Thomas’ NHS Foundation Trust in partnership with King’s College London (Grant code  
415 WT081878MA). JTR receives funding from the William and Mary Bauman Foundation, the Stan and  
416 Madelle Family Trust, and Research to Prevent Blindness. This study was funded in part by the OHSU  
417 Foundation (Collins Medical Trust) to JTR. LK receives funding supported by the Eunice Kennedy  
418 Shriver National Institute Of Child Health & Human Development of the National Institutes of Health  
419 under Award Number K12HD043488. We wish to acknowledge Dr. Erica Roberson, MD for her  
420 valuable contribution to study design; Patrick Stauffer and Sean Davin for technical assistance; and  
421 all OHSU patients and staff whom helped contribute samples for this study.

422

#### 423 REFERENCES

- 424 1. Brown MA, Kennedy LG, MacGregor AJ, Darke C, Duncan E, Shatford JL, et al.  
425 Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the  
426 environment. *Arthritis Rheum.* 1997;40(10):1823-8.
- 427 2. Pedersen OB, Svendsen AJ, Ejstrup L, Skytthe A, Harris JR, Junker P. Ankylosing  
428 spondylitis in Danish and Norwegian twins: occurrence and the relative importance of  
429 genetic vs. environmental effectors in disease causation. *Scand J Rheumatol.*  
430 2008;37(2):120-6.

- 431 3. MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, et al.  
432 Characterizing the quantitative genetic contribution to rheumatoid arthritis using data  
433 from twins. *Arthritis Rheum.* 2000;43(1):30-7.
- 434 4. van der Woude D, Houwing-Duistermaat JJ, Toes RE, Huizinga TW, Thomson W,  
435 Worthington J, et al. Quantitative heritability of anti-citrullinated protein antibody-  
436 positive and anti-citrullinated protein antibody-negative rheumatoid arthritis. *Arthritis*  
437 *Rheum.* 2009;60(4):916-23.
- 438 5. Mielants H, Veys EM, Cuvelier C, De Vos M, Botelberghe L. HLA-B27 related  
439 arthritis and bowel inflammation. Part 2. Ileocolonoscopy and bowel histology in  
440 patients with HLA-B27 related arthritis. *J Rheumatol.* 1985;12(2):294-8.
- 441 6. Ciccia F, Accardo-Palumbo A, Alessandro R, Rizzo A, Principe S, Peralta S, et al.  
442 Interleukin-22 and interleukin-22-producing NKp44+ natural killer cells in subclinical  
443 gut inflammation in ankylosing spondylitis. *Arthritis Rheum.* 2012;64(6):1869-78.
- 444 7. Martinez-Gonzalez O, Cantero-Hinojosa J, Paule-Sastre P, Gomez-Magan JC,  
445 Salvatierra-Rios D. Intestinal Permeability in Patients with Ankylosing Spondylitis and  
446 their healthy relatives. *Rheumatology.* 1994;33(7):644-7.
- 447 8. Mielants H, De Vos M, Goemaere S, Schelstraete K, Cuvelier C, Goethals K, et al.  
448 Intestinal mucosal permeability in inflammatory rheumatic diseases. II. Role of disease.  
449 *J Rheumatol.* 1991;18(3):394-400.
- 450 9. Morris AJ, Howden CW, Robertson C, Duncan A, Torley H, Sturrock RD, et al.  
451 Increased intestinal permeability in ankylosing spondylitis--primary lesion or drug  
452 effect? *Gut.* 1991;32(12):1470-2.
- 453 10. Vaile J, Meddings J, Yacyshyn B, AS. R, Maksymowych W. Bowel permeability and  
454 CD45RO expression on circulating CD20+ B cells in patients with ankylosing spondylitis  
455 and their relatives. *Journal of Rheumatology.* 1999  
456 26(1):128-35.
- 457 11. Bjarnason I, Helgason KO, Geirsson AJ, Sigthorsson G, Reynisdottir I,  
458 Gudbjartsson D, et al. Subclinical intestinal inflammation and sacroiliac changes in  
459 relatives of patients with ankylosing spondylitis. *Gastroenterology.* 2003;125(6):1598-  
460 605.
- 461 12. Palm O, Moum B, Ongre A, Gran JT. Prevalence of ankylosing spondylitis and  
462 other spondyloarthropathies among patients with inflammatory bowel disease: a  
463 population study (the IBSEN study). *J Rheumatol.* 2002;29(3):511-5.

- 464 13. Orchard TR, Holt H, Bradbury L, Hammersma J, McNally E, Jewell DP, et al. The  
465 prevalence, clinical features and association of HLA-B27 in sacroiliitis associated with  
466 established Crohn's disease. *Alimentary Pharmacology & Therapeutics*.  
467 2009;29(2):193-7.
- 468 14. Thjodleifsson B, Geirsson AJ, Bjornsson S, Bjarnason I. A common genetic  
469 background for inflammatory bowel disease and ankylosing spondylitis: a genealogic  
470 study in Iceland. *Arthritis Rheum*. 2007;56(8):2633-9.
- 471 15. Ellinghaus D, Jostins L, Spain SL, Cortes A, Bethune J, Han B, et al. Analysis of five  
472 chronic inflammatory diseases identifies 27 new associations and highlights disease-  
473 specific patterns at shared loci. *Nature genetics*. 2016;48(5):510-8.
- 474 16. Parkes M, Cortes A, van Heel DA, Brown MA. Genetic insights into common  
475 pathways and complex relationships among immune-mediated diseases. *Nat Rev Genet*.  
476 2013;14(9):661-73.
- 477 17. Cua DJ, Sherlock JP. Autoimmunity's collateral damage: Gut microbiota strikes  
478 'back'. *Nature medicine*. 2011;17(9):1055-6.
- 479 18. Costello ME, Elewaut D, Kenna TJ, Brown MA. Microbes, the gut and ankylosing  
480 spondylitis. *Arthritis research & therapy*. 2013;15(3):214.
- 481 19. Rosenbaum JT, Asquith M. The microbiome and HLA-B27-associated acute  
482 anterior uveitis. *Nature Reviews Rheumatology*. 2018:1.
- 483 20. Costello ME, Ciccia F, Willner D, Warrington N, Robinson PC, Gardiner B, et al.  
484 Brief Report: Intestinal Dysbiosis in Ankylosing Spondylitis. *Arthritis & rheumatology*.  
485 2015;67(3):686-91.
- 486 21. Wen C, Zheng Z, Shao T, Liu L, Xie Z, Le Chatelier E, et al. Quantitative  
487 metagenomics reveals unique gut microbiome biomarkers in ankylosing spondylitis.  
488 *Genome Biol*. 2017;18(1):142.
- 489 22. Breban M, Tap J, Leboime A, Said-Nahal R, Langella P, Chiochia G, et al. Faecal  
490 microbiota study reveals specific dysbiosis in spondyloarthritis. *Annals of the rheumatic  
491 diseases*. 2017;76(9):1614-22.
- 492 23. Gill T, Asquith M, Brooks SR, Rosenbaum JT, Colbert RA. Effects of HLA-B27 on  
493 Gut Microbiota in Experimental Spondyloarthritis Implicate an Ecological Model of  
494 Dysbiosis. *Arthritis & rheumatology*. 2017.

- 495 24. Scher JU, Szczesnak A, Longman RS, Segata N, Ubeda C, Bielski C, et al. Expansion  
496 of intestinal *Prevotella copri* correlates with enhanced susceptibility to arthritis. *Elife*.  
497 2013;2:e01202.
- 498 25. Zhang X, Zhang D, Jia H, Feng Q, Wang D, Liang D, et al. The oral and gut  
499 microbiomes are perturbed in rheumatoid arthritis and partly normalized after  
500 treatment. *Nature medicine*. 2015;21(8):895-905.
- 501 26. Jubair WK, Hendrickson JD, Severs EL, Schulz HM, Adhikari S, Ir D, et al.  
502 Modulation of Inflammatory Arthritis in Mice by Gut Microbiota Through Mucosal  
503 Inflammation and Autoantibody Generation. *Arthritis & rheumatology*.  
504 2018;70(8):1220-33.
- 505 27. Rogier R, Evans-Marin H, Manasson J, van der Kraan PM, Walgreen B, Helsen MM,  
506 et al. Alteration of the intestinal microbiome characterizes preclinical inflammatory  
507 arthritis in mice and its modulation attenuates established arthritis. *Sci Rep*.  
508 2017;7(1):15613.
- 509 28. Spor A, Koren O, Ley R. Unravelling the effects of the environment and host  
510 genotype on the gut microbiome. *Nat Rev Micro*. 2011;9(4):279-90.
- 511 29. Benson AK, Kelly SA, Legge R, Ma F, Low SJ, Kim J, et al. Individuality in gut  
512 microbiota composition is a complex polygenic trait shaped by multiple environmental  
513 and host genetic factors. *Proceedings of the National Academy of Sciences*.  
514 2010;107(44):18933-8.
- 515 30. Goodrich JK, Davenport ER, Beaumont M, Jackson MA, Knight R, Ober C, et al.  
516 Genetic Determinants of the Gut Microbiome in UK Twins. *Cell Host Microbe*.  
517 2016;19(5):731-43.
- 518 31. Kenna TJ, Brown MA. Immunopathogenesis of ankylosing spondylitis. *Int J Clin*  
519 *Rheumatol*. 2013;8(2):265-74.
- 520 32. Rosenbaum JT, Davey MP. Time for a gut check: Evidence for the hypothesis that  
521 HLA-B27 predisposes to ankylosing spondylitis by altering the microbiome. *Arthritis &*  
522 *Rheumatism*. 2011;63(11):3195-8.
- 523 33. Asquith MJ, Stauffer P, Davin S, Mitchell C, Lin P, Rosenbaum JT. Perturbed  
524 Mucosal Immunity and Dysbiosis Accompany Clinical Disease in a Rat Model of  
525 Spondyloarthritis. *Arthritis & rheumatology*. 2016;68(9):2151-62.





- 526 34. Lin P, Bach M, Asquith M, Lee AY, Akileswaran L, Stauffer P, et al. HLA-B27 and  
527 human beta2-microglobulin affect the gut microbiota of transgenic rats. *PLoS One*.  
528 2014;9(8):e105684.
- 529 35. Caminer AC, Haberman R, Scher JU. Human microbiome, infections, and  
530 rheumatic disease. *Clin Rheumatol*. 2017;36(12):2645-53.
- 531 36. Goodrich Julia K, Waters Jillian L, Poole Angela C, Sutter Jessica L, Koren O,  
532 Blekhman R, et al. Human Genetics Shape the Gut Microbiome. *Cell*. 2014;159(4):789-  
533 99.
- 534 37. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, et  
535 al. QIIME allows analysis of high-throughput community sequencing data. *Nat Meth*.  
536 2010;7(5):335-6.
- 537 38. DeSantis TZ, Hugenholtz P, Larsen N, Rojas M, Brodie EL, Keller K, et al.  
538 Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible  
539 with ARB. *Appl Environ Microbiol*. 2006;72(7):5069-72.
- 540 39. Edgar RC. Search and clustering orders of magnitude faster than BLAST.  
541 *Bioinformatics*. 2010;26(19):2460-1.
- 542 40. Lê Cao K-A, Costello M-E, Lakis VA, Bartolo F, Chua X-Y, Brazeilles R, et al. MixMC:  
543 a multivariate statistical framework to gain insight into microbial communities. *PLoS*  
544 *one*. 2016;11(8):e0160169.
- 545 41. Dixon PJJ, O'S. VEGAN, a package of R functions for community ecology.  
546 2003;14(6):927-30.
- 547 42. Langille MG, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, et al.  
548 Predictive functional profiling of microbial communities using 16S rRNA marker gene  
549 sequences. *Nat Biotechnol*. 2013;31(9):814-21.
- 550 43. Abubucker S, Segata N, Goll J, Schubert AM, Izard J, Cantarel BL, et al. Metabolic  
551 reconstruction for metagenomic data and its application to the human microbiome.  
552 *PLoS Comput Biol*. 2012;8(6):e1002358.
- 553 44. Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, et al. Dysfunction  
554 of the intestinal microbiome in inflammatory bowel disease and treatment. *Genome*  
555 *Biol*. 2012;13(9):R79.
- 556 45. Jia X, Han B, Onengut-Gumuscu S, Chen WM, Concannon PJ, Rich SS, et al.  
557 Imputing amino acid polymorphisms in human leukocyte antigens. *PLoS One*.  
558 2013;8(6):e64683.

- 559 46. Cortes A, Pulit SL, Leo PJ, Pointon JJ, Robinson PC, Weisman MH, et al. Major  
560 histocompatibility complex associations of ankylosing spondylitis are complex and  
561 involve further epistasis with ERAP1. *Nat Commun.* 2015;6:7146.
- 562 47. Chen Z, Qi J, Zheng X, Wu X, Li X, Gu J. AB0147 Faecal microbiota study identifies  
563 dysbiosis in ankylosing spondylitis patients. *BMJ Publishing Group Ltd*; 2018.
- 564 48. Tito RY, Cypers H, Joossens M, Varkas G, Van Praet L, Glorieus E, et al. Brief  
565 Report: *Dialister* as a Microbial Marker of Disease Activity in Spondyloarthritis. *Arthritis*  
566 *& rheumatology.* 2017;69(1):114-21.
- 567 49. Wu X, Liu J, Xiao L, Lu A, Zhang GJO, Cartilage. Alterations of Gut Microbiome in  
568 Rheumatoid Arthritis. 2017;25:S287-S8.
- 569 50. Turnbaugh PJ, Bäckhed F, Fulton L, Gordon JI. Diet-induced obesity is linked to  
570 marked but reversible alterations in the mouse distal gut microbiome. *Cell host &*  
571 *microbe.* 2008;3(4):213-23.
- 572 51. Turnbaugh PJ, Hamady M, Yatsunencko T, Cantarel BL, Duncan A, Ley RE, et al. A  
573 core gut microbiome in obese and lean twins. *nature.* 2009;457(7228):480.
- 574 52. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An  
575 obesity-associated gut microbiome with increased capacity for energy harvest. *nature.*  
576 2006;444(7122):1027.
- 577 53. Markle JGM, Frank DN, Mortin-Toth S, Robertson CE, Feazel LM, Rolle-Kampczyk  
578 U, et al. Sex Differences in the Gut Microbiome Drive Hormone-Dependent Regulation of  
579 Autoimmunity. *Science.* 2013;339(6123):1084-8.
- 580 54. Yurkovetskiy L, Burrows M, Khan Aly A, Graham L, Volchkov P, Becker L, et al.  
581 Gender Bias in Autoimmunity Is Influenced by Microbiota. *Immunity.* 2013;39(2):400-  
582 12.
- 583 55. Cortes A, Maksymowych WP, Wordsworth BP, Inman RD, Danoy P, Rahman P, et  
584 al. Association study of genes related to bone formation and resorption and the extent of  
585 radiographic change in ankylosing spondylitis. *Annals of the rheumatic diseases.*  
586 2015;74(7):1387-93.
- 587 56. Gomez A, Luckey D, Yeoman CJ, Marietta EV, Miller MEB, Murray JA, et al. Loss of  
588 sex and age driven differences in the gut microbiome characterize arthritis-susceptible\*  
589 0401 mice but not arthritis-resistant\* 0402 mice. *PloS one.* 2012;7(4):e36095.



- 590 57. Palm NW, de Zoete MR, Cullen TW, Barry NA, Stefanowski J, Hao L, et al.  
591 Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel  
592 disease. *Cell*. 2014;158(5):1000-10.
- 593 58. Viladomiu M, Kivolowitz C, Abdulhamid A, Dogan B, Victorio D, Castellanos JG, et  
594 al. IgA-coated *E. coli* enriched in Crohn's disease spondyloarthritis promote TH17-  
595 dependent inflammation. *Science translational medicine*. 2017;9(376):eaaf9655.
- 596 59. Nava GM, Friedrichsen HJ, Stappenbeck TS. Spatial organization of intestinal  
597 microbiota in the mouse ascending colon. *ISME J*. 2011;5(4):627-38.
- 598 60. Atarashi K, Tanoue T, Ando M, Kamada N, Nagano Y, Narushima S, et al. Th17 Cell  
599 Induction by Adhesion of Microbes to Intestinal Epithelial Cells. *Cell*. 2015;163(2):367-  
600 80.
- 601 61. Rothschild D, Weissbrod O, Barkan E, Kurilshikov A, Korem T, Zeevi D, et al.  
602 Environment dominates over host genetics in shaping human gut microbiota. *Nature*.  
603 2018;555(7695):210.
- 604 62. Manasson J, Shen N, Garcia Ferrer HR, Ubeda C, Iraheta I, Heguy A, et al. Gut  
605 microbiota perturbations in reactive arthritis and postinfectious spondyloarthritis.  
606 *Arthritis & rheumatology*. 2018;70(2):242-54.
- 607 63. Imhann F, Vila AV, Bonder MJ, Fu J, Gevers D, Visschedijk MC, et al. Interplay of  
608 host genetics and gut microbiota underlying the onset and clinical presentation of  
609 inflammatory bowel disease. *Gut*. 2018;67(1):108-19.
- 610 64. Olivares M, Neef A, Castillejo G, Palma GD, Varea V, Capilla A, et al. The HLA-DQ2  
611 genotype selects for early intestinal microbiota composition in infants at high risk of  
612 developing coeliac disease. *Gut*. 2015;64(3):406-17.
- 613 65. Wang J, Thingholm LB, Skiecevičienė J, Rausch P, Kummen M, Hov JR, et al.  
614 Genome-wide association analysis identifies variation in vitamin D receptor and other  
615 host factors influencing the gut microbiota. *Nature genetics*. 2016;48(11):1396.
- 616 66. Asquith M, Davin S, Stauffer P, Michell C, Janowitz C, Lin P, et al. Intestinal  
617 Metabolites Are Profoundly Altered in the Context of HLA-B27 Expression and  
618 Functionally Modulate Disease in a Rat Model of Spondyloarthritis. *Arthritis &*  
619 *rheumatology*. 2017;69(10):1984-95.
- 620 67. Asquith M, Sternes PR, Costello M-E, Karstens L, Diamond S, Martin TM, et al.  
621 HLA alleles associated with risk of ankylosing spondylitis and rheumatoid arthritis  
622 influence the gut microbiome. *bioRxiv*. 2019:517813.

# Author Manuscript






art\_40917\_f1.eps

Author Manuscript

**A****B**

art\_40917\_f2.eps

Author Manuscript

**A****B****C**

This article is protected by copyright. All rights reserved



Minerva Access is the Institutional Repository of The University of Melbourne

**Author/s:**

Asquith, M; Sternes, PR; Costello, M-E; Karstens, L; Diamond, S; Martin, TM; Li, Z; Marshall, MS; Spector, TD; Kim-Anh, LC; Rosenbaum, JT; Brown, MA

**Title:**

HLA Alleles Associated With Risk of Ankylosing Spondylitis and Rheumatoid Arthritis Influence the Gut Microbiome

**Date:**

2019-08-12

**Citation:**

Asquith, M., Sternes, P. R., Costello, M. -E., Karstens, L., Diamond, S., Martin, T. M., Li, Z., Marshall, M. S., Spector, T. D., Kim-Anh, L. C., Rosenbaum, J. T. & Brown, M. A. (2019). HLA Alleles Associated With Risk of Ankylosing Spondylitis and Rheumatoid Arthritis Influence the Gut Microbiome. *ARTHRITIS & RHEUMATOLOGY*, 71 (10), pp.1642-1650. <https://doi.org/10.1002/art.40917>.

**Persistent Link:**

<http://hdl.handle.net/11343/286292>

**File Description:**

Accepted version